Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 7Ovarian Neoplasms 5Breast Neoplasms 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1

Interventions

rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ATM Gene Mutation × rucaparib × Genitourinary × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡